GLOBAL MULTIOMICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global Multiomics Market Analysis & Forecast: 2025-2032

The Global Multiomics Market Size was valued at USD 2.47 Bn in 2025 and is expected to reach USD 6.73 Bn by 2032, growing at a compound annual growth rate (CAGR) of 15.4% from 2025 to 2032.

Key Takeaways

• By Product & Service, the Products segment will continue to lead the Global Multiomics Market share of 61.2% in 2025. This leadership is brought about by increased adoption of multiomics technologies and the growing demand for biological data analytics in drug discovery and precision medicine.
• North America is expected to dominate the Global Multiomics Market with over 42.1% market share in 2025. This is fueled by robust government funding, sophisticated healthcare infrastructure, and the adoption of next-generation multiomics multiomics platforms within the US and Canada.
• Asia Pacific is projected to capture over 31.2% of the global market by 2025 due to increasing investments in genomics and healthcare IT, as well as collaborations between domestic biotech companies and international counterparts.
• Europe is expected to hold 18.2% of the global market in 2025 driven by stronger acceptance of integrated omics for personalized medicine and sustained R&D spending bolstered by favorable marketing policies.

Market Overview:

Rising investment in public-private partnerships within the Global Multiomic Market growth is favorable for multiomics integration however, precision medicine is critically furthering its growth. Integrated omics methods such as genomics, proteomics, metabolomics and transcriptomics offer a more comprehensive understanding of biological systems which in turn drives crude insight into intricate disease mechanisms and facilitate robust insight into individual patient profiles, thereby transforming drug discovery, disease diagnostics, and precision medicine.

For instance, the US NIH draft Omnibus 2024 report reflecting multiomic integration for population health studies alongside EU funded Horizon Europe projects.

Current Events and Its Impact on the Global Multiomics Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Pricing Analysis

• The global Multiomics Market price quotations have a broad range across all products and services from sequencing and proteomics systems to single cell multiomics due to the different levels of technology used and their relevance.
• For sequencing, Ilumina makes high end systems like the NovaSeq 6000 which sells for between $985,000 and 1.2 million. Their Microarrays typically range from $300 to $1,200 per sample or array.
• Thermo Fisher Charges a premium for their Proteomics instruments like the Fusion Orbitrap Lumos mass spectrometer ranging from $800,000 to $1,200,000 as well as owning the Protein Arrays which sell for around $1-1,800 per array.
• Nuclear Magnetic Resonance allow the determination of the composition of raw materials, preparations and final products the spectrometers used range for $400,000 to $2.5 million depending on specifications while LC-MS systems go for $100,000 to $600,000.
• Single-cell multiomic platforms have their pricing set between 75,000 and 800,000 dollars due to the wide used range of the technology as well as the age.
• Pricing for those permits who pay generically ranges between $3000 and 15,000 conflicting with open sourced solutions that have no fees.
• Constantly having flexible pricing, cell layer sequencingand proteomics charge between $500 to $3000 per sample depending on the samples's complexity and depth.

Role of AI in the Global Multiomics Market

Artificial intelligence (AI) is fundamentally transforming the global Multiomics Market outlook by enabling advanced analysis of vast, complex biological datasets. With the market projected to expand at a robust 32.2% CAGR from 2025 to 2032, AI is pivotal in overcoming challenges associated with integrating genomics, proteomics, and metabolomics data. Key areas where AI is reshaping multiomics include:

• The Use of AI in Multiomics Frameworks: Multiomics sequencing technologies have incorporated AI with industry leaders like Illumina. For instance, their NovaSeq™ X Series implements AI for intricate base and variant calling, attaining an astonishing 99.9% accuracy in genomic evaluations. Such AI-Driven data integration facilitates enormous scale data advancement, minimal error rates, and accelerates research from cancer biomarker identification to population genomics within record time.
• AI Technology for Enhanced Biological Insight Extraction: These AI-enabled technologies led by Biomodal, like the duet multiomics solution, which uses deep learning AI algorithms, perform multilayered epigenetic and genetic data analysis on a per-cell basis. Notably, Johns Hopkins-affiliated researchers applied this technology to uncover DNA methylation markers indicative of pre-symptomatic Alzheimer’s disease and completed the analysis 40% faster than traditional methods. This illustrates how complex omics data can be translated into biological actions with the help of AI.
• Transforming Medicine Tailored to Patients with AI: AI Integrated Multiomics Lab from Vizzhy Inc is a prime example, utilizing AI to integrate transcriptomic, proteomic, and metabolomic data with clinical information using specialized neural networks. Offering personalized treatment pathways for metabolic ailments, this system was introduced in early 2024, shortening drug development timelines by 30% and improving patient outcome metrics by 25%.

As AI models continue to evolve—addressing challenges like data standardization and model interpretability—the synergy between AI and multiomics is set to become a cornerstone of next-generation biomedical innovation, unlocking transformative opportunities across healthcare and life sciences.

End-User Feedback

• IVF Clinics: Multiomics technologies are increasingly adopted in IVF clinics to enhance embryo selection processes and deepen understanding of genetic factors influencing fertility. This integration has contributed to improved clinical success rates and personalized treatment approaches.

• Biotechnology and Pharmaceutical Companies: These organizations leverage multiomics platforms extensively in drug discovery and development. The approach facilitates identification of novel therapeutic targets and supports the advancement of personalized medicine, driving innovation across the pipeline.

• Research and Academic Institutions: Multiomics is a critical tool in academic and research settings for conducting comprehensive studies on disease mechanisms. Strong government funding and collaborative initiatives further enable these institutions to advance multiomics-based research.

• Biobanks: By integrating multiomics data, biobanks are significantly increasing the utility and value of stored biological samples. This supports a broad range of research projects and enhances data-driven discoveries.

Segmental Analysis

To learn more about this report, Download Free Sample

Global Multiomics Market Insights, By Product & Service: Product Segment Leads Market Share

The product segment is expected to dominate the global Multiomics Market Demand holding 61.2% share in 2025. This dominance is driven by the increasing adoption of advanced multiomics products that enable comprehensive biological data analysis, supporting precision medicine, biomarker discovery, and therapeutic development. The growing demand for high-quality, integrated multiomics platforms is fueling investments in product innovations and expanding market opportunities.

Regional Insights

To learn more about this report, Download Free Sample

North America Multiomics Market Analysis and Trends

North America is estimated to account for 42.1% of the share in the global Multiomics Market forecast in 2025, which further solidifies their lead in the market. The market dominance stems from the large number of multiomic life sciences and biotechnology companies operating in R&D. World renowned universities and research centers in the U.S. and Canada have also been contributing to the advanced multiomics projects which pushes innovation in precision medicine, biomarker therapeutics and their development.

Asia Pacific Multiomics Market Analysis and Trends

In 2025 Asia Pacific is expected to reach around 31.2% and position itself as the second largest in the global Multiomics Market trend. This growth can be attributed to the growing focus on genomics and healthcare IT investment in the region especially to India, Japan, and China. These funds will allow for more efficient biological data management.

Immuno-Oncology Assays Market Dominating Countries

United States Multiomics Market Analysis and Trends

The U.S. remains the dominant contributor within North America’s Multiomics Market share. The country’s leadership stems from substantial investments by government agencies like the National Institutes of Health (NIH) and private sector players focused on multiomics-driven personalized healthcare solutions.

In 2024, numerous U.S.-based biotech firms and academic institutions accelerated research efforts integrating genomics, proteomics, and metabolomics data for disease diagnosis and drug development. The availability of sophisticated multiomics platforms and bioinformatics tools in clinical and research settings bolsters the U.S. market’s growth trajectory.

China Multiomics Market Analysis and Trends

China is a leading force in Asia Pacific’s multiomics growth, driven by massive public and private funding towards genomics research and healthcare innovation. The Chinese government’s strategic initiatives to develop precision medicine and biotechnology ecosystems encourage technology development and adoption. Research centers in China are increasingly utilizing multiomics technologies to tackle complex diseases, supporting a rapidly growing market with expanding application areas.

Market Report Scope

Global Multiomics Market- Drivers

• Increasing usage of multiomics in personalized medicine:

The rapidly growing field of personalized medicine is fueling the expansion of the multiomics market. Personalized medicine seeks to tailor healthcare treatments and interventions to the individual characteristics of each patient, taking into account factors such as their genetic makeup, protein expression levels, and metabolic profiles.

Multiomics is the integrated analysis of multiple types of big biological data, such as genomics, epigenomics, proteomics, metabolomics, and lipidomics, to develop comprehensive insights into health and disease at a systems level.

• Growing investment and funding in multiomics research:

Multiomics holds tremendous promise for advancing biological understanding and improving human health. The integration of multiple -omics data types such as genomics, transcriptomics, proteomics, and metabolomics provides a more comprehensive view of biological systems compared to single-omics.

This has led to increased investments from both private and public funding agencies in multiomics research. Several biopharmaceutical and diagnostics companies are devoting more resources towards multiomics as it could help drug discovery and development. For example, they are funding multiomics studies to better understand disease pathways and identify novel drug targets or biomarkers. The National Institutes of Health (NIH) in the U.S. has also identified multiomics as a top priority area.

Global Multiomics Market- Opportunities

• Emergence of cloud computing and artificial intelligence in multiomics data analysis:

The emergence of cloud computing and artificial intelligence is presenting a huge opportunity for multiomics data analysis in the life sciences field. Advancements in DNA sequencing technologies and other omics tools have led to an explosion in large and complex multiomics datasets. However, analyzing these vast amounts of diverse biological data using traditional on-premise computing methods is challenging and time consuming for researchers and laboratories.

Cloud service offers vast scalable computing resources that can be easily provisioned on demand. Researchers can leverage elastic cloud infrastructures to seamlessly analyze petabytes of multiomics datasets without having to make large upfront capital investments in their own IT infrastructure.

• Scope for multiomics in development of biomarkers for disease diagnosis: ‘

The scope for multiomics in the development of biomarkers for disease diagnosis presents a great opportunity in the multiomics market. Integration of multiomics approaches like genomics, epigenomics, transcriptomics, proteomics, and metabolomics provides a more comprehensive understanding of biological systems and disease pathways. Biomarkers developed using multiomics could enable early and accurate diagnosis of diseases.

This is a huge clinical unmet need as most diseases are currently diagnosed at a late stage when treatment options are limited. By combining multiple types of omics data, multiomics studies provide insights that are not possible through individual omics approaches alone. This results in discovery of novel biomarker signatures composed of genetic, protein and metabolic factors.

For example, a 2021 study that integrated data from over 28,000 patient samples across 11 cancer types was able to identify biomarkers based on molecular subtypes which can help personalize cancer treatment. Such multiomics derived biomarkers have great potential to revolutionize precision diagnosis and enable stratification of patients for targeted therapies.

Global Multiomics Market- Trends

• Adoption of spatially resolved multiomics analysis:

The adoption of spatially resolved multiomics analysis techniques is having a significant influence on the emerging multiomics market. Spatially resolved analysis allows researchers to study biological samples with single-cell or spatial resolution, revealing insights that were previously impossible to see with bulk tissue analysis.

This cutting-edge approach provides a more detailed understanding of complex biological systems by capturing information about how different omics factors interact and change across spatial dimensions within a tissue sample.

• Launch of new commercial multiomics platforms with enhanced capabilities: 

The launch of new commercial multiomics platforms with enhanced capabilities is significantly influencing the multiomics market growth. These new platforms are allowing researchers to gain richer insights through integrated analysis of different levels of biological data. By combining various omics datasets such as genomics, transcriptomics, proteomics, and metabolomics from a single sample, they provide a more comprehensive understanding of biological systems and pathways.

For example, companies are introducing platforms that can perform multiomics analysis at an unprecedented scale and depth. Instruments from companies, such as Illumina, now support the analysis of millions of cells simultaneously at single-cell resolution. This allows researchers to detect even rare cell types and changes in cellular states. Similarly, other platforms effectively combine multi-omics analysis with spatial profiling techniques using microscopy.

Analyst’s Views

• The multiomics market is poised to grow significantly in the coming years. Driven by advancements in genomics, proteomics, and other "omics" technologies, the ability to analyze multiple biological data sets from a single sample is revolutionizing life science research.
• This integrated multiomics approach allows researchers to develop more comprehensive understanding of health and disease. In the Asia Pacific region, especially China, is expected to dominate the market due to increasing healthcare expenditure and government support from biotech research. However, North America will continue its dominance overall due to a strong foothold of global players and extensive R&D activities in the region.
• On the technological front, the development of high-throughput and affordable multiomics platforms will reduce costs and drive faster market adoption. Availability of cloud-based multiomics data analysis solutions is another major opportunity to boost the market growth.
• However, lack of skilled workforce and high costs involved remain key challenges. Data management and integration across different omics layers is a major technological restraint. Establishing standards for multiomics data processing and sharing will help address this issue to some extent. Successful implementation of multiomics approaches in clinical research and precision medicine also depends on overcoming regulatory hurdles around data usage.

Global Multiomics Market- Recent Developments

• In April 2025, Biomodal introduced its upgraded duet multiomics platform featuring enhanced deep learning algorithms for simultaneous genetic and epigenetic analysis at the single-cell level. This update significantly reduces analysis time and increases sensitivity for early disease biomarker detection.
• On March 15, 2025, Illumina launched the NovaSeq™ X Series Ultra, an advanced sequencing system integrated with AI-powered analytics to improve genomic data accuracy and processing speed. This innovation is expected to accelerate large-scale multiomics research in oncology and population genomics.
• In February 2025, Vizzhy Inc. inaugurated its AI-powered Multiomics Lab in Bengaluru, combining transcriptomic, proteomic, and metabolomic data with clinical records to tailor personalized treatment plans. Early reports indicate a 30% reduction in drug discovery timelines and improved patient outcomes for metabolic disorders.
• On January 20, 2025, Thermo Fisher Scientific unveiled its latest Orbitrap Fusion Lumos X mass spectrometer, incorporating AI-driven spectral interpretation tools to enhance proteomics throughput and data quality, enabling faster biomarker discovery across various therapeutic areas.

Market Segmentation:

• Global Multiomics Market, By Product & Service
  • Products
    • Instruments
    • Consumables
    • Software
  • Services
• Global Multiomics Market, By Type
  • Single-cell Multiomics
  • Bulk Multiomics
• Global Multiomics Market, By Platform
  • Genomics
  • Transcriptomics
  • Proteomics
  • Metabolomics
  • Integrated Omics Platforms
• Global Multiomics Market, By Application
  • Diagnostics
  • Drug Discovery and Development
  • Personalized Medicine
  • AgriGenomics
  • Others (Environmental Monitoring, etc.)
• Global Multiomics Market, By End User
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Clinical Research Organizations (CROs)
  • Others (Hospitals and Diagnostic Centers, etc.)
• Global Multiomics Market, By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Global Multiomics Market, Key Players
  • BD
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc
  • Danaher, PerkinElmer Inc.
  • Shimadzu Corporation
  • Bruker
  • QIAGEN
  • Agilent Technologies, Inc.
  • BGI

Sources

Primary Research interviews:

• Key Opinion Leaders (KOLs)
• Industry Experts
• Market Participants
• Stakeholders
• Others

Databases:

• GenBank
• UniProt
• NCBI
• Others

Magazines:

• Nature
• Science
• Molecular Cell
• Cell
• Others

Journals:

• Nucleic Acids Research
• Genome Biology
• Nature Methods
• Others

Newspapers:

• The New York Times
• The Wall Street Journal
• The Guardian
• The Washington Post
• Others

Associations

:

• International Society for Computational Biology (ISCB)
• American Society for Biochemistry and Molecular Biology (ASBMB)
• European Molecular Biology Organization (EMBO)
• American Association for Cancer Research (AACR)
• Others

Public Domain sources:

• World Health Organization (WHO)
• National Institutes of Health (NIH)
• European Bioinformatics Institute (EBI)
• National Center for Biotechnology Information (NCBI)
• Others

Proprietary Elements:

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 8 years

*Definition: Multiomics assays allow researchers to analyze various biological data sets such as genome, transcriptome, proteome, or metabolome simultaneously. The major techniques involved are genomics, which studies the structure and function of genomes. Transcriptomics examines the transcripts in a genome through RNA sequencing. Proteomics looks at protein expression using techniques like mass spectrometry. Metabolomics analyzes small molecule metabolites and helps understand metabolic pathways. Combining the information obtained from different omics techniques provides the opportunity to understand how biological systems function as a whole.